Amgen Q3 Earnings: Will Strong Drug Sales Offset Headwinds?

Amgen is scheduled to report Q3 2026 results on Nov. 3, with consensus estimates of $9.95 billion in sales and $5.74 per share in earnings; results have not yet been reported. Expected growth in Repatha, Evenity, Tezspire and Uplizna may be offset by biosimilar erosion in Prolia and Xgeva, weakness in Otezla and Enbrel, and a meaningful sequential increase in operating expenses. Amgen's Earnings ESP is -1.82%, and the article's model does not signal a conclusive earnings beat; investors are also awaiting an update on obesity candidate MariTide.

Analysis

The key issue is mix, not simply whether AMGN clears the quarterly EPS bar: growth in newer products must outpace both patent-driven erosion and price pressure, while higher operating expense can absorb the incremental sales. A headline beat driven by timing or cost deferral would be less durable than evidence that newer launches are replacing lost Prolia/Xgeva revenue on a sustained basis.

Competitive effects cut both ways. AMGN’s biosimilar launches can support its own revenue while adding pressure to JNJ’s Stelara franchise and REGN’s Eylea business; the relevant question is whether adoption produces meaningful scale, not just sequential growth. Conversely, accelerating biosimilar competition in AMGN’s legacy products could pressure the durability investors assign to its growth portfolio. The MariTide update is a separate, longer-duration valuation catalyst: absent concrete clinical data or a clear timeline, pipeline commentary alone may not justify extrapolating obesity-market potential.

Near term (Nov. 3), the elevated event risk and reported year-to-date outperformance argue against assuming another positive reaction from an earnings beat. Over 1–3 months, watch management’s outlook for legacy-product erosion, pricing/340B effects, and operating expense. Over 6–18 months, the thesis depends on launch growth and MariTide data converting into credible revenue potential. Falsifiers: stabilization in Prolia/Xgeva sales or better-than-feared expense guidance weakens the downside case; accelerating erosion, weaker launch uptake, or a less favorable MariTide update strengthens it. No valuation or options-pricing data are provided, so avoid assigning a price target or recommending a pre-event options structure.

Key Decisions for Investors

• Do not chase AMGN ahead of the Nov. 3 print; treat the event as a two-sided catalyst rather than infer an earnings beat from its prior surprise history.
• After results, consider a defined-risk bearish AMGN position only if guidance or commentary indicates legacy erosion is outpacing launch growth and operating costs are rising without a credible offset. Reassess if Prolia/Xgeva trends stabilize or expense guidance improves.
• Track JNJ and REGN for evidence that AMGN’s Stelara and Eylea biosimilars are affecting originator demand; sequential biosimilar growth alone is not proof of material share transfer.
• Keep MariTide on a catalyst watchlist, not as a standalone trade until the company provides verifiable clinical evidence and a more specific development timeline.